We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+11.93%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.58B
AUM Growth
+$232M
Cap. Flow
+$52.5K
Cap. Flow %
0%
Top 10 Hldgs %
43.75%
Holding
149
New
7
Increased
20
Reduced
25
Closed
10

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$60.3M
2
JNJ icon
Johnson & Johnson
JNJ
+$32.4M
3
VTRS icon
Viatris
VTRS
+$16.7M
4
MCK icon
McKesson
MCK
+$14.4M
5
TMO icon
Thermo Fisher Scientific
TMO
+$13.3M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$28.8M
2
MDCO
Medicines Co
MDCO
+$26.2M
3
INCY icon
Incyte
INCY
+$23.8M
4
ABT icon
Abbott
ABT
+$18.6M
5
CNC icon
Centene
CNC
+$17.1M

Sector Composition

Rank Sector Weight
1 Healthcare 91.08%
2 Real Estate 3.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DOC
51
DELISTED
PHYSICIANS REALTY TRUST
DOC
$10.5M 0.41%
530,672
– –
XLV icon
52
State Street Health Care Select Sector SPDR ETF
XLV
$42.2B
$10.5M 0.41%
+140,600
New +$10.2M
CNC icon
53
Centene
CNC
$30.1B
$10.3M 0.4%
288,600
-511,400
-64% -$17.1M
PVLA
54
Palvella Therapeutics
PVLA
$2.15B
$10.2M 0.4%
49,251
-2,573
-5% -$455K
ENDP
55
DELISTED
Endo International plc
ENDP
$10.2M 0.4%
914,548
– –
BMY icon
56
Bristol-Myers Squibb
BMY
$132B
$10.1M 0.39%
+186,500
New +$10.2M
ACHC icon
57
Acadia Healthcare
ACHC
$2.62B
$10.1M 0.39%
231,200
+166,300
+256% +$6.75M
LKFT
58
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$9.97M 0.39%
115,738
– –
PBYI icon
59
Puma Biotechnology
PBYI
$402M
$9.68M 0.38%
260,200
– –
CCP
60
DELISTED
Care Capital Properties, Inc.
CCP
$9.27M 0.36%
345,022
– –
TTPH
61
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$9.23M 0.36%
50,216
+40,600
+422% +$4.55M
CTMX icon
62
CytomX Therapeutics
CTMX
$714M
$9.15M 0.36%
530,092
-225,998
-30% -$2.97M
ARDX icon
63
Ardelyx
ARDX
$1.25B
$8.09M 0.31%
639,370
– –
ADAP
64
DELISTED
Adaptimmune Therapeutics
ADAP
$8.08M 0.31%
1,466,368
+900,000
+159% +$3.94M
AKRX
65
DELISTED
Akorn Inc
AKRX
$7.89M 0.31%
327,735
– –
NTRA icon
66
Natera
NTRA
$38.6B
$7.83M 0.3%
882,358
– –
KPTI icon
67
Karyopharm Therapeutics
KPTI
$159M
$7.77M 0.3%
40,348
+6,993
+21% +$1.12M
CLLS
68
Cellectis
CLLS
$287M
$7.45M 0.29%
310,250
– –
MNTA
69
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$6.73M 0.26%
504,400
+197,800
+65% +$3.1M
PRAH
70
DELISTED
PRA Health Sciences, Inc.
PRAH
$6.65M 0.26%
102,000
– –
LTC
71
LTC Properties
LTC
$2.06B
$6.53M 0.25%
136,212
– –
SAGE
72
DELISTED
Sage Therapeutics
SAGE
$6.43M 0.25%
90,480
+36,480
+68% +$2.14M
GBT
73
DELISTED
Global Blood Therapeutics, Inc.
GBT
$6.36M 0.25%
172,500
-208,800
-55% -$5.26M
CAH icon
74
Cardinal Health
CAH
$53.2B
$6.25M 0.24%
76,600
-75,900
-50% -$5.97M
EPZM
75
DELISTED
Epizyme, Inc
EPZM
$6.21M 0.24%
362,000
-38,000
-10% -$506K
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2017 Portfolio in Review

As of Q1 2017, Tekla Capital Management held 149 positions worth $2.58B, up 9.9% from $2.35B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Tekla Capital Management's Q1 2017 filing shows 7 new, 20 increased, 25 reduced and 10 closed positions. Its largest new stake was State Street Health Care Select Sector SPDR ETF: 140,600 shares worth $10.5M. The largest sale was Allergan plc, an estimated $28.8M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 91% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q1 2017 buy was State Street Health Care Select Sector SPDR ETF: 140,600 shares worth $10.5M.
  • Tekla Capital Management added most to Amgen in Q1 2017, an estimated $60.3M increase.
  • Tekla Capital Management's biggest Q1 2017 reduction was Allergan plc, cutting an estimated $28.8M.
  • Tekla Capital Management fully exited Medicines Co in Q1 2017, selling an estimated $26.2M.
  • Tekla Capital Management's ten largest holdings make up 44% of its $2.58B portfolio in Q1 2017.
  • Tekla Capital Management opened 7 new positions and closed 10 in Q1 2017.
  • Tekla Capital Management's portfolio value rose 9.9% quarter-over-quarter to $2.58B.

Based on Tekla Capital Management's 13F filing for Q1 2017, filed 12 May 2017.